newsfilter
← Interviews
Milken Institute33 min

Conversation with FDA Commissioner Marty Makary & CMS Admin Mehmet Oz | Future of Health Summit 2025

Marty Makary, Mehmet Oz, Esther Krofah

Conference Presentation, Fireside Chat

The administration is driving a comprehensive healthcare overhaul that combines aggressive drug pricing strategies like "Most Favored Nation" with FDA reforms designed to slash biosimilar development times by reducing regulatory hurdles and replacing animal testing with computational models. Simultaneously, federal agencies are deploying $3 billion in savings from terminated contracts and AI tools to combat $100 billion in annual fraud while restructuring internal operations to accelerate clinical trial reviews and ensure domestic supply chain security. These initiatives aim to bridge the gap between the U.S.'s $4.9 trillion annual health expenditure and its lagging life expectancy by fostering data interoperability, enforcing new transparency rules, and launching the "Trump Rx" initiative to secure lower-cost, domestically produced medications for consumers.